Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets

Molecular Pharmaceutics

Volumn 12, Issue 7, 2015, Pages 2436-2443

  Vaithianathan, Soundarya ^a   Raman, Siddarth ^a   Jiang, Wenlei ^b   Ting, Tricia Y ^c   Kane, Maureen A ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

bioequivalence; Biopharmaceutics Classification System (BCS); brand; Caco 2 permeability; generic; lamotrigine; quality

Indexed keywords

GENERIC DRUG; LAMOTRIGINE; METOPROLOL; ANTICONVULSIVE AGENT; TABLET; TRIAZINE DERIVATIVE;

ANALYTIC METHOD; APPARENT PERMEABILITY; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CLINICAL ASSESSMENT; DISSOLUTION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SOLUBILITY; DRUG SURVEILLANCE PROGRAM; FREEZE DRYING; PH; PRIORITY JOURNAL; RISK ASSESSMENT; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET FRIABILITY; THERAPEUTIC EQUIVALENCE; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; PERMEABILITY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TABLET; TUMOR CELL LINE;

ANTICONVULSANTS; BIOPHARMACEUTICS; CACO-2 CELLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; HUMANS; METOPROLOL; PERMEABILITY; RISK ASSESSMENT; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY; TRIAZINES;

EID: 84936746800     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00154     Document Type: Article

References (37)

1. Bialer, M. Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue? Epilepsia 2007, 48 (10) 1825-1832
2. Berg, M. J.; Gross, R. A.; Haskins, L. S.; Zingaro, W. M.; Tomaszewski, K. J. Generic substitution in the treatment of epilepsy: Patient and physician perceptions Epilepsy Behavior 2008, 13, 693-699
3. Privitera, M. D. Generic antiepileptic drugs: Current controversies and future directions Epilepsy Currents 2008, 8, 113-117
4. Chuang, K.; Krauss, G. L.; Cao, Y. J. Evaluating FDA bioequivalence standards for generic carbamazepine formulations Neurology 2009, 72, A226
5. Bialer, M.; Midha, K. K. Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability Epilepsia 2010, 51 (6) 941-950
6. Ligue Francaise Contre L'Epilepsie (LFCE). Recommendation on the use of generic for the treatment of epilepsy. http://www.ilae-epilepsy.org (accessed January 29, 2015).
7. Perucca, E.; Albani, F.; Capovilla, G.; Bernardina, B. D.; Michelucci, R.; Zaccara, G. Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs Epilepsia 2006, 47, 16-20
8. Liow, K.; Barkley, G. L.; Pollard, J. R.; Harden, C. L.; Bazil, C. W. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy Neurology 2007, 68, 1249-1250
9. American Epilepsy Society (AES). Position statement on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. http://www.AESNET.org (accessed January 29, 2015).
10. Amidon, G. L.; Lennerna¨s, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
11. Council of Experts. Lamotrigine Tablets; U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention: Rockville, MD, 2011; pp 3264-3266.
12. Yu, L. X.; Carlin, A. S.; Amidon, G. L.; Hussain, A. S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs Int. J. Pharm. 2003, 270, 221-227
13. Council of Experts. Disintegration; U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention: Rockville, MD, 2011; pp 276-277.
14. Council of Experts. Loss on Drying; U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention: Rockville, MD, 2011; pp 304-305.
15. Tolle-Sander, S.; Grill, A.; Joshi, H.; Kapil, R.; Persiani, S.; Polli, J. E. Characterization of Dexloxiglumide In Vitro Biopharmaceutical Properties and Active Transport J. Pharm. Sci. 2003, 92 (10) 1968-1980
16. Lentz, K. A.; Hayashi, J.; Lucisano, L. J.; Polli, J. E. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system Int. J. Pharm. 2000, 200, 41-51
17. Incecayir, T.; Tsume, Y.; Amidon, G. L. Comparison of the Permeability of Metoprolol and Labetolol in Rat, Mouse, and Caco-2 Cells: Use as a Reference Standard for BCS Classification Mol. Pharmaceutics 2013, 10, 958-966
18. Polli, J. E.; Yu, L. X.; Cook, J. A.; Amidon, G. L.; Borchardt, R. T.; Burnside, B. A.; Burton, P. S.; Chen, M.; Conner, D. P.; Faustino, P. J.; Hawi, A. A.; Hussain, A. S.; Joshi, H. N.; Kwei, G.; Lee, V. H. L.; Lesko, L. J.; Lipper, R. A.; Loper, A. E.; Nerurkar, S. G.; Polli, J. W.; Sanvordeker, D. R.; Taneja, R.; Uppoor, R. S.; Vattikonda, C. S.; Wilding, I.; Zhang, G. Summary workshop report: Biopharmaceutics classification system-implementation challenges and extension opportunities J. Pharm. Sci. 2004, 93 (6) 1375-1381
19. Council of Experts. The Dissolution Procedure: Development and Validation; U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention: Rockville, MD, 2011; pp 624-630.
20. SUPAC Expert Working Group of the Chemistry Manufacturing Controls Coordinating Committee (CMC CC) of the Center for Drug Evaluation and Research. Guidance for Industry Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. http://www.fda.gov/downloads/Drugs/Guidances/UCM070636.pdf, 1995, (accessed January 28, 2015).
21. Polli, J. E. In Vitro Studies Are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-release Solid Oral Dosage Forms AAPS J. 2008, 10 (2) 289-299
22. GlaxoSmithKline Product Information. http://us.gsk.com/products/assets/us-lamictal.pdf (accessed January 28, 2015).
23. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2012, 64, 4-17
24. Butler, J. M.; Dressman, J. B. The developability classification system: Application of biopharmaceutics concepts to formulation development J. Pharm. Sci. 2010, 99 (12) 4940-4954
25. CDER/FDA. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System, 2000.
26. Tsume, Y.; Mudie, D. M.; Langguth, P.; Amidon, G. E.; Amidon, G. L. The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIC Eur. J. Pharm. Sci. 2014, 57, 152-163
27. CDER/FDA. Dissolution Methods. http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm (accessed May 4, 2015).
28. CDER/FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/queryai.cfm (accessed May 4, 2015).
29. CDER/FDA. Guidance on Lamotrigine. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm209231.pdf (accessed May 4, 2015).
30. CDER/FDA. Inactive Ingredient Search for Approved Products. http://www.accessdata.fda.gov/scripts/cder/iig/index.Cfm (accessed February 17, 2015).
31. Rowland, A.; Elliot, D. J.; Williams, A.; Mackenzie, P. I.; Dickinson, R. G.; Miners, J. O. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valrpoic acid interaction Drug Metab. Dispos. 2006, 34 (6) 1055-1062
32. Tompkins, L.; Lynch, C.; Haidar, S.; Polli, J. E.; Wang, H. Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells Pharm. Res. 2010, 27 (8) 1703-1712
33. Ramey, P.; Osborn, M.; Abou-Khalil, B. Conversion from immediate-release to extended-release lamotrigine improves seizure control Epilepsy Res. 2014, 108, 1637-1641
34. Biton, V.; Shneker, B. F.; Nanitoku, D.; Hammer, A. E.; Vuong, A.; Caldwell, P. T.; Messenheimer, J. A. Long-Term Tolerability and Safety of Lamotrigine Extended-Release: Pooled Analysis of Three Clinical Trials Clin. Drug Invest. 2013, 38, 359-364
35. GlaxoSmithKline Product Information. https://www.gsksource.com/gskprm/htdocs/documents/LAMICTAL-XR-PI-MG.PDF (accessed February 16, 2015).
36. CDER/FDA. Clinical Pharmacology and Biopharmaceutics Reviews. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022115s000-ClinPharmR.pdf (accessed February 16, 2015).
37. Tompson, D. J.; Ali, I.; Oliver-Willwon, R.; Job, S.; Zhu, L.; Lemme, F.; Hammer, A. E.; Vuong, A.; Messenheimer, J. A. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study) Epilepsia 2008, 49 (3) 410-417